Lee O'Brien, PhD, RAC, is a seasoned professional in regulatory affairs and translational medicine, boasting over 18 years of experience in developing innovative therapies for rare diseases and effective regulatory strategies. Lee has held significant roles at organizations such as Roivant Sciences, Sarepta Therapeutics, Aruvant Sciences, Takeda, and Eli Lilly, where they crafted strategies for various therapeutic areas, including neuroscience and oncology. With a strong foundation in both research and regulatory compliance, Lee is committed to advancing novel medicines for patients with unmet medical needs while actively engaging in regulatory intelligence efforts. Lee earned a PhD in Pathology and Molecular Medicine from Queen's University, along with a Master’s degree in Medical Science from McMaster University and a Bachelor of Applied Science from Laurentian University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices